<DOC>
	<DOCNO>NCT02495233</DOCNO>
	<brief_summary>The purpose Phase 1b part study evaluate safety tolerability ASP2215 combination erlotinib determine recommend phase 2 dose ( RP2D ) ASP2215 . The purpose Phase 2 part study evaluate objective response rate ( ORR ) RP2D ASP2215 combination erlotinib .</brief_summary>
	<brief_title>A Study ASP2215 Combination With Erlotinib Subjects With Epidermal Growth Factor Receptor ( EGFR ) Activating Mutation-Positive ( EGFRm+ ) Advanced Non-Small-Cell Lung Cancer ( NSCLC ) Who Have Acquired Resistance EGFR Tyrosine Kinase Inhibitor ( TKI )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Subject histologically cytologically confirm metastatic locally advanced , unresectable nonsmallcell lung cancer ( NSCLC ) . Subject document exon 19 deletion exon 21 L858R EGFR activate mutation . Subject receive prior treatment EGFR tyrosine kinase inhibitor Subject Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 screening . Subject adequate organ function . Female subject must either : Be nonchildbearing potential : Or , childbearing potential , 1 . Agree try become pregnant study 45 day final study drug administration 2 . And negative serum pregnancy test screen 3 . And , heterosexually active , agree consistently use 2 form highly effective birth control Male subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control Phase 1b Subjects : Subject expect show therapeutic response exist available treatment . Intervening anticancer treatment subsequent EGFR TKI allow ( require ) . Additional inclusion criterion phase 2 Subjects : Subject NSCLC tissue sample obtain subject developed resistance EGFR TKI therapy available central test . Subject 's baseline tumor specimen ( obtain subject develop resistance EGFR TKI therapy ) T790M negative . Subject receive EGFR TKI least 6 month progress therapy within past 28 day . Subject intervene anticancer treatment subsequent EGFR TKI exception radiotherapy allow occur least 14 day prior first dose study drug . Subject least 1 measureable lesion ( include lesion irradiate ) base Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Subject ongoing toxicity great equal grade 3 ( NCI CTCAE version 4.03 ) attributable prior NSCLC treatment time screen . Subject receive agent antitumor activity ( EGFR inhibitor , include T790M inhibitor ) include chemotherapy , radiotherapy , immunotherapy , within 14 day prior first dose study drug ( palliative radiotherapy allow ) . Subject receive ASP2215 previously . Subject receive blood transfusion hematopoietic growth factor therapy within 14 day prior first dose study drug . Subject major surgical procedure ( studyrelated biopsy ) within 14 day prior first dose study drug , major surgical procedure plan occur study . Subject active hepatitis B C active hepatic disorder . Subject know human immunodeficiency virus ( HIV ) infection . Subject symptomatic central nervous system ( CNS ) metastasis . Subjects asymptomatic , untreated CNS metastasis allow . Subjects previously treat currently asymptomatic CNS metastasis eligible provided meet follow : Any whole brain radiotherapy ( WBRT ) complete least 2 week prior first dose study drug . Any stereotactic radiosurgery ( SRS ) complete least 1 week prior first dose study drug . Subject require steroid require escalate dos steroid least 2 week prior first dose study drug . Subject evidence active infection require systemic therapy within 14 day prior first dose study drug . Subject uncontrolled hypertension . Subject severe uncontrolled systemic disease active bleeding diatheses . Subject history druginduced interstitial lung disease evidence active interstitial lung disease . Subject ongoing cardiac arrhythmia ( include atrial fibrillation ) grade â‰¥ 2 . Subject currently Class 3 4 New York Heart Association congestive heart failure . Subject history severe/unstable angina , myocardial infarction cerebrovascular accident within 6 month prior first dose study drug . Subject history gastrointestinal ulcer within 28 day prior first dose study drug . Subject history gastrointestinal bleeding within 90 day prior first dose study drug . Subject concurrent corneal disorder ophthalmologic condition make subject unsuitable study participation . Subject condition make subject unsuitable study participation . Subject hypokalemia hypomagnesemia screening . Subject QTcF interval &gt; 450 m 12lead ECG screening . Subject know long QT syndrome . Subject take medication know prolong QT interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Erlotinib</keyword>
	<keyword>ASP2215</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
</DOC>